Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Durvalumab + Tremelimumab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Poughkeepsie, New York
This trial is testing a new combination therapy for patients with advanced lung cancer who have not yet been treated. The new therapy combines two drugs, durvalumab and tremelimumab. The trial will compare this new therapy to standard chemotherapy to see if it is more effective and has fewer side effects.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.